UNSPSC 51291514: Fenmetozole hydrochloride

This classification denotes an antidepressant agent with the molecular formula C10H10Cl2N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AIW7IL0D0B, chemically known as 2-imidazoline, 2-((3,4-dichlorophenoxy)methyl)-, monohydrochloride but more generally known as fenmetozole hydrochloride, which bears US NIH Compound Identifier 32048. Most nations, for tariff and trade purposes, schedule fenmetozole hydrochloride under HS 29332990 and SITC 51573.

As of Q4 2014, FENMETOZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenmetozole hydrochloride bears US NLM identifiers UMLS ID C2825656 and NCI Concept Code C81486. SMILES: C1CC(C(CC1OCC2=NCCN2)CL)CL.CL.

UNSPSC 51291514 Fenmetozole hydrochloride is a Commodity code that nominally identifies a specific chemical compound, but recent state and local procurement activity tagged under this code does not align with fenmetozole hydrochloride procurement. Instead, the opportunities solicited involve naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—none of which are fenmetozole hydrochloride or closely related active pharmaceutical ingredients. The code shows little relevant recent activity for the substance it nominally describes. State and local governments are using this code designation inconsistently or inappropriately across health-related pharmaceutical and medical supply procurement.

The three recent opportunities span health departments and cooperative purchasing alliances across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, with awarded vendors effective July 1, 2026. The mismatch between the code's stated substance and the actual procurement scope suggests that this Commodity code is either misconfigured in state and local procurement systems or applied as a catch-all for pharmaceutical and medical supply categories where more precise codes are unavailable.